604 related articles for article (PubMed ID: 26867490)
21. Targeting Interleukin-6 Signaling in Clinic.
Kang S; Tanaka T; Narazaki M; Kishimoto T
Immunity; 2019 Apr; 50(4):1007-1023. PubMed ID: 30995492
[TBL] [Abstract][Full Text] [Related]
22. Bile acids inhibit interleukin-6 signaling via gp130 receptor-dependent and -independent pathways in rat liver.
Graf D; Kohlmann C; Haselow K; Gehrmann T; Bode JG; Häussinger D
Hepatology; 2006 Nov; 44(5):1206-17. PubMed ID: 17058237
[TBL] [Abstract][Full Text] [Related]
23. Novel path to IL-6 trans-signaling through thrombin-induced soluble IL-6 receptor release by platelets.
Marino M; Scuderi F; Ponte E; Maiuri MT; De Cristofaro R; Provenzano C; Rose-John S; Cittadini A; Bartoccioni E
J Biol Regul Homeost Agents; 2013; 27(3):841-52. PubMed ID: 24152848
[TBL] [Abstract][Full Text] [Related]
24. IL-6 trans-signaling is essential for the development of hepatocellular carcinoma in mice.
Bergmann J; Müller M; Baumann N; Reichert M; Heneweer C; Bolik J; Lücke K; Gruber S; Carambia A; Boretius S; Leuschner I; Becker T; Rabe B; Herkel J; Wunderlich FT; Mittrücker HW; Rose-John S; Schmidt-Arras D
Hepatology; 2017 Jan; 65(1):89-103. PubMed ID: 27770462
[TBL] [Abstract][Full Text] [Related]
25. Interleukin 6 inhibits proliferation and, in cooperation with an epidermal growth factor receptor autocrine loop, increases migration of T47D breast cancer cells.
Badache A; Hynes NE
Cancer Res; 2001 Jan; 61(1):383-91. PubMed ID: 11196191
[TBL] [Abstract][Full Text] [Related]
26. Early hepatocyte DNA synthetic response posthepatectomy is modulated by IL-6 trans-signaling and PI3K/AKT activation.
Nechemia-Arbely Y; Shriki A; Denz U; Drucker C; Scheller J; Raub J; Pappo O; Rose-John S; Galun E; Axelrod JH
J Hepatol; 2011 May; 54(5):922-9. PubMed ID: 21145830
[TBL] [Abstract][Full Text] [Related]
27. The JAK-inhibitor, JAB/SOCS-1 selectively inhibits cytokine-induced, but not v-Src induced JAK-STAT activation.
Iwamoto T; Senga T; Naito Y; Matsuda S; Miyake Y; Yoshimura A; Hamaguchi M
Oncogene; 2000 Sep; 19(41):4795-801. PubMed ID: 11032030
[TBL] [Abstract][Full Text] [Related]
28. Interleukin 6 and its receptor: ten years later.
Hirano T
Int Rev Immunol; 1998; 16(3-4):249-84. PubMed ID: 9505191
[TBL] [Abstract][Full Text] [Related]
29. Growth-suppressive activity of raloxifene on liver cancer cells by targeting IL-6/GP130 signaling.
Wang Y; Ma H; Zhao C; Liu T; Yan D; Jou D; Li H; Zhang C; Lü J; Li C; Lin J; Li S; Lin L
Oncotarget; 2017 May; 8(20):33683-33693. PubMed ID: 28430601
[TBL] [Abstract][Full Text] [Related]
30. Essential roles of IL-6 trans-signaling in colonic epithelial cells, induced by the IL-6/soluble-IL-6 receptor derived from lamina propria macrophages, on the development of colitis-associated premalignant cancer in a murine model.
Matsumoto S; Hara T; Mitsuyama K; Yamamoto M; Tsuruta O; Sata M; Scheller J; Rose-John S; Kado S; Takada T
J Immunol; 2010 Feb; 184(3):1543-51. PubMed ID: 20042582
[TBL] [Abstract][Full Text] [Related]
31. Interleukin-6 receptor signaling. I. gp80 and gp130 receptor interaction in the absence of interleukin-6.
Gaillard JP; Mani JC; Liautard J; Klein B; Brochier J
Eur Cytokine Netw; 1999 Mar; 10(1):43-8. PubMed ID: 10210772
[TBL] [Abstract][Full Text] [Related]
32. Regulation of pre-B cell colony-enhancing factor by STAT-3-dependent interleukin-6 trans-signaling: implications in the pathogenesis of rheumatoid arthritis.
Nowell MA; Richards PJ; Fielding CA; Ognjanovic S; Topley N; Williams AS; Bryant-Greenwood G; Jones SA
Arthritis Rheum; 2006 Jul; 54(7):2084-95. PubMed ID: 16802343
[TBL] [Abstract][Full Text] [Related]
33. The IL-6-gp130-STAT3 pathway in hepatocytes triggers liver protection in T cell-mediated liver injury.
Klein C; Wüstefeld T; Assmus U; Roskams T; Rose-John S; Müller M; Manns MP; Ernst M; Trautwein C
J Clin Invest; 2005 Apr; 115(4):860-9. PubMed ID: 15761498
[TBL] [Abstract][Full Text] [Related]
34. The soluble IL-6 receptors: serum levels and biological function.
Montero-Julian FA
Cell Mol Biol (Noisy-le-grand); 2001 Jun; 47(4):583-97. PubMed ID: 11502067
[TBL] [Abstract][Full Text] [Related]
35. Soluble IL-6 receptor potentiates the antagonistic activity of soluble gp130 on IL-6 responses.
Müller-Newen G; Küster A; Hemmann U; Keul R; Horsten U; Martens A; Graeve L; Wijdenes J; Heinrich PC
J Immunol; 1998 Dec; 161(11):6347-55. PubMed ID: 9834125
[TBL] [Abstract][Full Text] [Related]
36. The role of the inhibitors of interleukin-6 signal transduction SHP2 and SOCS3 for desensitization of interleukin-6 signalling.
Fischer P; Lehmann U; Sobota RM; Schmitz J; Niemand C; Linnemann S; Haan S; Behrmann I; Yoshimura A; Johnston JA; Müller-Newen G; Heinrich PC; Schaper F
Biochem J; 2004 Mar; 378(Pt 2):449-60. PubMed ID: 14611646
[TBL] [Abstract][Full Text] [Related]
37. Long non-coding RNA DILC regulates liver cancer stem cells via IL-6/STAT3 axis.
Wang X; Sun W; Shen W; Xia M; Chen C; Xiang D; Ning B; Cui X; Li H; Li X; Ding J; Wang H
J Hepatol; 2016 Jun; 64(6):1283-94. PubMed ID: 26812074
[TBL] [Abstract][Full Text] [Related]
38. IL-6/IL-6 receptor system and its role in physiological and pathological conditions.
Mihara M; Hashizume M; Yoshida H; Suzuki M; Shiina M
Clin Sci (Lond); 2012 Feb; 122(4):143-59. PubMed ID: 22029668
[TBL] [Abstract][Full Text] [Related]
39. [Basic and clinical aspects of IL-6].
Nakajima K; Hirano T
Gan To Kagaku Ryoho; 1991 Apr; 18(4):505-14. PubMed ID: 1707253
[TBL] [Abstract][Full Text] [Related]
40. The IL-6/gp130/STAT3 signaling axis: recent advances towards specific inhibition.
Garbers C; Aparicio-Siegmund S; Rose-John S
Curr Opin Immunol; 2015 Jun; 34():75-82. PubMed ID: 25749511
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
